References
- WHO. Dementia . www.who.int/mediacentre/factsheets/fs362/en/ .
- Egan MF Kost J Tariot PN et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease . N. Engl. J. Med.378 ( 18 ), 1691 – 1703 ( 2018 ).
- Coric V Salloway S van Dyck CH et al. Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial . JAMA Neurol.72 ( 11 ), 1324 – 1333 ( 2015 ).
- Honig LS Vellas B Woodward M et al. Trial of Solanezumab for mild dementia due to Alzheimer's disease . N. Engl. J. Med.378 ( 4 ), 321 – 330 ( 2018 ).
- Cavalli A Bolognesi ML Minarini A et al. Multi-target-directed ligands to combat neurodegenerative diseases . J. Med. Chem.51 ( 3 ), 347 – 372 ( 2008 ).
- León R Garcia AG Marco-Contelles J . Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease . Med. Res. Rev.33 ( 1 ), 139 – 189 ( 2013 ).
- Ismaili L Refouvelet B Benchekroun M et al. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease . Prog. Neurobiol.151 , 4 – 34 ( 2017 ).
- Oset-Gasque MJ Marco-Contelles J . Alzheimer's disease, the “one-molecule, one-target” paradigm, and the multitarget directed ligand approach . ACS Chem. Neurosci.9 ( 3 ), 401 – 403 ( 2018 ).
- Benchekroun M Romero A Egea J et al. The antioxidant additive approach for Alzheimer's disease therapy: new ferulic (lipoic) acid plus melatonin modified tacrines as cholinesterases inhibitors, direct antioxidants, and nuclear factor (erythroid-derived 2)-like 2 activators . J. Med. Chem.59 ( 21 ), 9967 – 9973 ( 2016 ).
- Butini S Brindisi M Brogi S et al. Multifunctional cholinesterase and amyloid beta fibrillization modulators. Synthesis and biological investigation . ACS Med. Chem. Lett.4 ( 12 ), 1178 – 1182 ( 2013 ).
- Brogi S Butini S Maramai S et al. Disease-modifying anti-Alzheimer's drugs: inhibitors of human cholinesterases interfering with β-amyloid aggregation . CNS Neurosci. Ther.20 ( 7 ), 624 – 632 ( 2014 ).
- Jaiteh M Zeifman A Saarinen M et al. Docking screens for dual inhibitors of disparate drug targets for Parkinson's disease . J. Med. Chem.61 ( 12 ), 5269 – 5278 ( 2018 ).
- Bautista-Aguilera MÓ Hagenow S Palomino-Antolin A et al. Multitarget-directed ligands combining cholinesterase and monoamine oxidase inhibition with histamine H3R antagonism for neurodegenerative diseases . Angew. Chem. Int. Ed. Engl.56 ( 41 ), 12765 – 12769 ( 2017 ).
- Ramsay RR Majekova M Medina M Valoti M . Key targets for multi-target ligands designed to combat neurodegeneration . Front. Neurosci.10 , doi:10.3389/fnins.2016.00375 ( 2016 ) ( Online article ).